Table 2

Clinical features of patients with diagnosis of COVID-19 confirmed by rhinopharyngeal swab and chest X-ray

Patient 1Patient 2Patient 3Patient 4
DiagnosisTakayasu arteritisTakayasu arteritisCranial GCACranial GCA
Age, years38337979
ComorbiditiesHypertensionSmokingHypertensionCAD, CKD
Disease status at last visitRemissionRemissionRemissionRemission
Disease duration, months99111513
Prednisone, mg5517.57.5
csDMARD (duration, months)MTX 20 mg (82)MTX 20 mg (105)
bDMARD (duration, months)IFX 10 mg/kg (75)ADA 40 mg (27)
Contact with COVID-19+NoYesYesNo
Rhinopharyngeal swabPositivePositivePositivePositive
Chest X-ray findingsPneumoniaPneumoniaPneumoniaPneumonia
Chest CT findings Not done Not done Interstitial pneumoniaInterstitial pneumonia
Hospital admissionNoNoYes*Yes
CRP levels (mg/L)
 On admission42 mg/L51 mg/L
 At discharge8 mg/L11 mg/L
TherapyNoneNoneHCQ 400 mg dailyHCQ 400 mg daily
Length of hospitalisation8 days19 days
OutcomeFull recoveryFull recoveryFull recoveryFull recovery
  • *COVID-19 developed during hospital admission for a different medical reason.

  • bDMARD, biological disease-modifying antirheumatic drug; CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GCA, giant cell arteritis; HCQ, hydroxychloroquine; IFX, infliximab; MTX, methotrexate.